TJS would like to thank the support from National Institutes of Health (NIH), including R01-AG082273 (NIA), R01-AG071682 (NIA), and Pilot Grant, COBRE Chemical Biology Infectious Disease (P20-GM113117, NIGMS).
Author contributions
EF, ALA, and VDP equally contributed to: Methodology, Software, Validation, Formal analysis, Investigation, Data curation, Writing—original draft. FS and MDL: Data curation, Formal analysis, Software, Visualization, Writing—review & editing. TJS and KK: Conceptualization, Supervision, Project administration, Writing—review & editing. TJS: Funding acquisition.
Conflicts of interest
The authors declare no conflicts of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
The data used for this study are included in the manuscript and the supplementary files.
Funding
This study was supported by National Institutes of Health (NIH) [R01-AG082273, NIA and R01-AG071682, NIA]; Pilot Grant, COBRE Chemical Biology Infectious Disease [P20-GM113117, NIGMS]; NIH Shared Instrumentation Grant [#S10RR024664]; NSF Major Research Instrumentation Award [#1625923]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Laksitorini M, Prasasty VD, Kiptoo PK, Siahaan TJ. Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.Ther Deliv. 2014;5:1143–63. [DOI] [PubMed] [PMC]
Pardridge WM. A Historical Review of Brain Drug Delivery.Pharmaceutics. 2022;14:1283. [DOI] [PubMed] [PMC]
Stamatovic SM, Johnson AM, Keep RF, Andjelkovic AV. Junctional proteins of the blood-brain barrier: New insights into function and dysfunction.Tissue Barriers. 2016;4:e1154641. [DOI] [PubMed] [PMC]
Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton.Biochim Biophys Acta. 2008;1778:660–9. [DOI] [PubMed] [PMC]
Adson A, Raub TJ, Burton PS, Barsuhn CL, Hilgers AR, Audus KL, et al. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers.J Pharm Sci. 1994;83:1529–36. [DOI] [PubMed]
Boggon TJ, Murray J, Chappuis-Flament S, Wong E, Gumbiner BM, Shapiro L. C-cadherin ectodomain structure and implications for cell adhesion mechanisms.Science. 2002;296:1308–13. [DOI] [PubMed]
Zheng K, Trivedi M, Siahaan TJ. Structure and function of the intercellular junctions: barrier of paracellular drug delivery.Curr Pharm Des. 2006;12:2813–24. [DOI] [PubMed]
Nagar B, Overduin M, Ikura M, Rini JM. Structural basis of calcium-induced E-cadherin rigidification and dimerization.Nature. 1996;380:360–4. [DOI] [PubMed]
Sinaga E, Jois SD, Avery M, Makagiansar IT, Tambunan US, Audus KL, et al. Increasing paracellular porosity by E-cadherin peptides: discovery of bulge and groove regions in the EC1-domain of E-cadherin.Pharm Res. 2002;19:1170–9. [DOI] [PubMed]
Kiptoo P, Sinaga E, Calcagno AM, Zhao H, Kobayashi N, Tambunan US, et al. Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides.Mol Pharm. 2011;8:239–49. [DOI] [PubMed] [PMC]
On NH, Kiptoo P, Siahaan TJ, Miller DW. Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide.Mol Pharm. 2014;11:974–81. [DOI] [PubMed] [PMC]
Ulapane KR, On N, Kiptoo P, Williams TD, Miller DW, Siahaan TJ. Improving Brain Delivery of Biomolecules via BBB Modulation in Mouse and Rat: Detection using MRI, NIRF, and Mass Spectrometry.Nanotheranostics. 2017;1:217–31. [DOI] [PubMed] [PMC]
Sajesh BV, On NH, Omar R, Alrushaid S, Kopec BM, Wang WG, et al. Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors.Pharmaceutics. 2019;11:481. [DOI] [PubMed] [PMC]
Ulapane KR, Kopec BM, Siahaan TJ. Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides.Pharmaceutics. 2019;11:568. [DOI] [PubMed] [PMC]
Ulapane KR, Kopec BM, Siahaan TJ. In Vivo Brain Delivery and Brain Deposition of Proteins with Various Sizes.Mol Pharm. 2019;16:4878–89. [DOI] [PubMed] [PMC]
Alaofi A, Farokhi E, Prasasty VD, Anbanandam A, Kuczera K, Siahaan TJ. Probing the interaction between cHAVc3 peptide and the EC1 domain of E-cadherin using NMR and molecular dynamics simulations.J Biomol Struct Dyn. 2017;35:92–104. [DOI] [PubMed] [PMC]
Takeda H. cis-Dimer formation of E-cadherin is independent of cell-cell adhesion assembly in vivo.Biochem Biophys Res Commun. 2004;316:822–6. [DOI] [PubMed]
Chappuis-Flament S, Wong E, Hicks LD, Kay CM, Gumbiner BM. Multiple cadherin extracellular repeats mediate homophilic binding and adhesion.J Cell Biol. 2001;154:231–43. [DOI] [PubMed] [PMC]
Takeda H, Shimoyama Y, Nagafuchi A, Hirohashi S. E-cadherin functions as a cis-dimer at the cell-cell adhesive interface in vivo.Nat Struct Biol. 1999;6:310–2. [DOI] [PubMed]
Pertz O, Bozic D, Koch AW, Fauser C, Brancaccio A, Engel J. A new crystal structure, Ca2+ dependence and mutational analysis reveal molecular details of E-cadherin homoassociation.EMBO J. 1999;18:1738–47. [DOI] [PubMed] [PMC]
Laksitorini MD, Kiptoo PK, On NH, Thliveris JA, Miller DW, Siahaan TJ. Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability.J Pharm Sci. 2015;104:1065–75. [DOI] [PubMed] [PMC]
Prasasty VD, Krause ME, Tambunan US, Anbanandam A, Laurence JS, Siahaan TJ. 1H, 13C and 15N backbone assignment of the EC-1 domain of human E-cadherin.Biomol NMR Assign. 2015;9:31–5. [DOI] [PubMed] [PMC]
Lee W, Tonelli M, Markley JL. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy.Bioinformatics. 2015;31:1325–7. [DOI] [PubMed] [PMC]
Dominguez C, Boelens R, Bonvin AM. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information.J Am Chem Soc. 2003;125:1731–7. [DOI] [PubMed]
Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery.J Chem Inf Model. 2011;51:2778–86. [DOI] [PubMed]
Skinner AL, Laurence JS. Probing residue-specific interactions in the stabilization of proteins using high-resolution NMR: a study of disulfide bond compensation.J Pharm Sci. 2010;99:2643–54. [DOI] [PubMed] [PMC]
Parisini E, Higgins JM, Liu JH, Brenner MB, Wang JH. The crystal structure of human E-cadherin domains 1 and 2, and comparison with other cadherins in the context of adhesion mechanism.J Mol Biol. 2007;373:401–11. [DOI] [PubMed] [PMC]
Angst BD, Marcozzi C, Magee AI. The cadherin superfamily: diversity in form and function.J Cell Sci. 2001;114:629–41. [DOI] [PubMed]
van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin.Cell Mol Life Sci. 2008;65:3756–88. [DOI] [PubMed] [PMC]
Koch AW, Manzur KL, Shan W. Structure-based models of cadherin-mediated cell adhesion: the evolution continues.Cell Mol Life Sci. 2004;61:1884–95. [DOI] [PubMed] [PMC]
Koch AW, Pokutta S, Lustig A, Engel J. Calcium binding and homoassociation of E-cadherin domains.Biochemistry. 1997;36:7697–705. [DOI] [PubMed]
Troyanovsky RB, Sokolov E, Troyanovsky SM. Adhesive and lateral E-cadherin dimers are mediated by the same interface.Mol Cell Biol. 2003;23:7965–72. [DOI] [PubMed] [PMC]
Patel SD, Ciatto C, Chen CP, Bahna F, Rajebhosale M, Arkus N, et al. Type II cadherin ectodomain structures: implications for classical cadherin specificity.Cell. 2006;124:1255–68. [DOI] [PubMed]
Miloushev VZ, Bahna F, Ciatto C, Ahlsen G, Honig B, Shapiro L, et al. Dynamic properties of a type II cadherin adhesive domain: implications for the mechanism of strand-swapping of classical cadherins.Structure. 2008;16:1195–205. [DOI] [PubMed] [PMC]
Vunnam N, Pedigo S. Calcium-induced strain in the monomer promotes dimerization in neural cadherin.Biochemistry. 2011;50:8437–44. [DOI] [PubMed]
Davila S, Liu P, Smith A, Marshall AG, Pedigo S. Spontaneous Calcium-Independent Dimerization of the Isolated First Domain of Neural Cadherin.Biochemistry. 2018;57:6404–15. [DOI] [PubMed]
Overduin M, Harvey TS, Bagby S, Tong KI, Yau P, Takeichi M, et al. Solution structure of the epithelial cadherin domain responsible for selective cell adhesion.Science. 1995;267:386–9. [DOI] [PubMed]
Kim SA, Tai CY, Mok LP, Mosser EA, Schuman EM. Calcium-dependent dynamics of cadherin interactions at cell-cell junctions.Proc Natl Acad Sci U S A. 2011;108:9857–62. [DOI] [PubMed] [PMC]
Kopec BM, Kiptoo P, Zhao L, Rosa-Molinar E, Siahaan TJ. Noninvasive Brain Delivery and Efficacy of BDNF to Stimulate Neuroregeneration and Suppression of Disease Relapse in EAE Mice.Mol Pharm. 2020;17:404–16. [DOI] [PubMed] [PMC]
Kopec BM, Zhao L, Rosa-Molinar E, Siahaan TJ. Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice as a Model of Alzheimer’s Disease.Med Res Arch. 2020;8:2043. [DOI] [PubMed] [PMC]
Elballa W, Schwinghamer K, Ebert E, Siahaan TJ. Peptides and Their Delivery to the Brain. In: Jois SD, editor. Peptide Therapeutics: Fundamentals of Design, Development, and Delivery. Cham: Springer International Publishing; 2022. pp. 237–66. [DOI]
Doolittle ND, Muldoon LL, Culp AY, Neuwelt EA. Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.Adv Pharmacol. 2014;71:203–43. [DOI] [PubMed] [PMC]
Smith QR. Quantitation of Blood-Brain Barrier Permeability. In: Neuwelt EA, editor. Implications of the Blood-Brain Barrier and Its Manipulation: Volume 1 Basic Science Aspects. Boston, MA: Springer US; 1989. pp. 85–118. [DOI]
Neuwelt EA, Barnett PA, McCormick CI, Frenkel EP, Minna JD. Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain.Neurosurgery. 1985;17:419–23. [DOI] [PubMed]
Neuwelt EA, Specht HD, Barnett PA, Dahlborg SA, Miley A, Larson SM, et al. Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system.Neurosurgery. 1987;20:885–95. [DOI] [PubMed]
Fishman PS, Fischell JM. Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases.Front Neurol. 2021;12:749047. [DOI] [PubMed] [PMC]
Iyer J, Akkad A, Tang N, Berens M, Zenhausern F, Gu J. EXTH-17. A FOCUSED ULTRASOUND BLOOD BRAIN BARRIER DISRUPTION MODEL TO TEST THE INFLUENCE OF TIGHT JUNCTION GENES TO TREAT BRAIN TUMORS.Neuro-Oncol. 2021;23:vi167. [DOI]
Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport.Brain Res Bull. 2003;60:297–306. [DOI] [PubMed]
Zwanziger D, Hackel D, Staat C, Böcker A, Brack A, Beyermann M, et al. A peptidomimetic tight junction modulator to improve regional analgesia.Mol Pharm. 2012;9:1785–94. [DOI] [PubMed]
Ansbro MR, Shukla S, Ambudkar SV, Yuspa SH, Li L. Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.PLoS One. 2013;8:e60334. [DOI] [PubMed] [PMC]
Li Y, Zheng X, Gong M, Zhang J. Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma.Oncotarget. 2016;7:79401–7. [DOI] [PubMed] [PMC]
Kim JA, Casalini T, Brambilla D, Leroux JC. Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency.Sci Rep. 2016;6:34297. [DOI] [PubMed] [PMC]
Oller-Salvia B, Sánchez-Navarro M, Giralt E, Teixidó M. Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery.Chem Soc Rev. 2016;45:4690–707. [DOI] [PubMed]
Tanaka A, Furubayashi T, Arai M, Inoue D, Kimura S, Kiriyama A, et al. Delivery of Oxytocin to the Brain for the Treatment of Autism Spectrum Disorder by Nasal Application.Mol Pharm. 2018;15:1105–11. [DOI] [PubMed]
Samaridou E, Alonso MJ. Nose-to-brain peptide delivery – The potential of nanotechnology.Bioorg Med Chem. 2018;26:2888–905. [DOI] [PubMed]
